SLC5A5 and thyroid gland undifferentiated (anaplastic) carcinoma: Drug loaded nanocarriers for the treatment of anaplastic thyroid cancer have been developed to address the abnormal expression of the NIS, as current treatment methods are suboptimal [121,122].